CD86 and neoplasm: For instance, a recent study indicates that a subset of neutrophils displaying antigen-presenting markers such as HLA-DR, CD80, and CD86 can transport tumor antigens into TDLNs during early stages of head and neck cancer, thereby initiating a tumor-specific immune response [9].